Clinical trial

Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

NCT04305236

Study summary

ClinicalTrials.gov

Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Abemaciclib Normalized identity: abemaciclib View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Fulvestrant Normalized identity: fulvestrant View linked drug · Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2020-07-23

PhasePHASE2

Conditions

Breast Neoplasmverified · MONDO: breast neoplasm

Hormone Receptor Positive Breast Carcinomaunresolved

Interventions

AbemaciclibDRUG · verified · RxNorm: abemaciclib

FulvestrantDRUG · verified · RxNorm: fulvestrant

Sponsors & collaborators

University of California, Irvinelead sponsor

Eli Lilly and Companycollaborator

Mapped research locations

OrangeCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04305236 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.